Kairos Pharma Ltd. (KAPA)
0.505
+0.03
(+6.65%)
USD |
NYAM |
Nov 03, 16:00
0.486
-0.02
(-3.76%)
After-Hours: 20:00
Kairos Pharma Enterprise Value : -1.080M for Nov. 3, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 03, 2026 | -1.080M |
| November 02, 2026 | -1.177M |
| October 30, 2026 | -1.004M |
| October 29, 2026 | -0.973M |
| October 28, 2026 | -1.025M |
| October 27, 2026 | -1.004M |
| October 26, 2026 | -0.9853M |
| October 23, 2026 | -0.9167M |
| October 22, 2026 | -0.9611M |
| October 21, 2026 | -0.8613M |
| October 20, 2026 | -0.8396M |
| October 19, 2026 | -0.8812M |
| October 16, 2026 | -0.7857M |
| October 15, 2026 | -0.5736M |
| October 14, 2026 | -0.352M |
| October 13, 2026 | -0.0898M |
| October 12, 2026 | -0.0797M |
| October 09, 2026 | -0.1461M |
| October 08, 2026 | 0.3105M |
| October 07, 2026 | 0.0366M |
| October 06, 2026 | 0.8936M |
| October 05, 2026 | 2.118M |
| October 02, 2026 | 2.148M |
| October 01, 2026 | 2.148M |
| September 30, 2026 | 2.393M |
| Date | Value |
|---|---|
| September 29, 2026 | 2.454M |
| September 28, 2026 | 2.516M |
| September 25, 2026 | 2.638M |
| September 24, 2026 | 2.791M |
| September 23, 2026 | 2.669M |
| September 22, 2026 | 2.822M |
| September 21, 2026 | 2.852M |
| September 18, 2026 | 2.669M |
| September 17, 2026 | 2.914M |
| September 16, 2026 | 2.914M |
| September 15, 2026 | 3.036M |
| September 14, 2026 | 3.005M |
| September 11, 2026 | 2.754M |
| September 10, 2026 | 2.516M |
| September 09, 2026 | 2.454M |
| September 08, 2026 | 2.791M |
| September 04, 2026 | 3.005M |
| September 03, 2026 | 2.485M |
| September 02, 2026 | 2.210M |
| September 01, 2026 | 2.424M |
| August 31, 2026 | 2.516M |
| August 28, 2026 | 2.454M |
| August 27, 2026 | 2.537M |
| August 26, 2026 | 2.944M |
| August 25, 2026 | 2.691M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.658B |
| Alnylam Pharmaceuticals, Inc. | 20.81B |
| Anika Therapeutics, Inc. | 247.14M |
| Savara, Inc. | 833.02M |
| Vericel Corp. | 2.035B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.388M |
| Total Expenses (Quarterly) | 1.388M |
| EPS Diluted (Quarterly) | -0.4536 |
| Earnings Yield | -385.7% |
| Normalized Earnings Yield | -372.44 |